ES2113882T3 - Vacuna oral que comprende un antigeno asociado superficialmente con eritrocitos. - Google Patents

Vacuna oral que comprende un antigeno asociado superficialmente con eritrocitos.

Info

Publication number
ES2113882T3
ES2113882T3 ES91908727T ES91908727T ES2113882T3 ES 2113882 T3 ES2113882 T3 ES 2113882T3 ES 91908727 T ES91908727 T ES 91908727T ES 91908727 T ES91908727 T ES 91908727T ES 2113882 T3 ES2113882 T3 ES 2113882T3
Authority
ES
Spain
Prior art keywords
pct
erythrocytes
antigen associated
associated surface
date oct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91908727T
Other languages
English (en)
Inventor
Gerald Toh Pang
Robert Llewellyn Clancy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flustat Pty Ltd
Original Assignee
Flustat Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flustat Pty Ltd filed Critical Flustat Pty Ltd
Application granted granted Critical
Publication of ES2113882T3 publication Critical patent/ES2113882T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

LAS CELULAS ROJAS DE LA SANGRE O LOS DERIVADOS DE LAS MISMAS PUEDEN ACTUAR COMO PORTADORES POTENTES PARA ANTIGENOS ORALMENTE ADMINISTRADOS. EN PARTICULAR, PUEDE INDUCIRSE DE MANERA EFECTIVA LA INMUNIDAD DE LAS MUCOSAS CONTRA VIRUS COMO EL "INFLUENZA" CUANDO SE ENCUENTRA ABSORBIDO EN CELULAS ROJAS DE LA SANGRE DE POLLOS Y SE ADMINISTRA ORALMENTE.
ES91908727T 1990-04-24 1991-04-24 Vacuna oral que comprende un antigeno asociado superficialmente con eritrocitos. Expired - Lifetime ES2113882T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPJ978390 1990-04-24
PCT/AU1991/000159 WO1991016073A1 (en) 1990-04-24 1991-04-24 Oral vaccine comprising antigen surface-associated with red blood cells

Publications (1)

Publication Number Publication Date
ES2113882T3 true ES2113882T3 (es) 1998-05-16

Family

ID=3774614

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91908727T Expired - Lifetime ES2113882T3 (es) 1990-04-24 1991-04-24 Vacuna oral que comprende un antigeno asociado superficialmente con eritrocitos.

Country Status (15)

Country Link
US (1) US5643577A (es)
EP (1) EP0528859B1 (es)
JP (1) JPH05506233A (es)
KR (1) KR100186783B1 (es)
AT (1) ATE162402T1 (es)
AU (1) AU646257B2 (es)
BR (1) BR9106374A (es)
CA (1) CA2080477A1 (es)
DE (1) DE69128782T2 (es)
DK (1) DK0528859T3 (es)
ES (1) ES2113882T3 (es)
GR (1) GR3026569T3 (es)
HK (1) HK1004060A1 (es)
SG (1) SG46225A1 (es)
WO (1) WO1991016073A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882649A (en) * 1990-04-24 1999-03-16 Flustat Pty. Ltd. Oral vaccine comprising antigen surface-associated with red blood cells
GB2294268A (en) 1994-07-07 1996-04-24 Procter & Gamble Bleaching composition for dishwasher use
GB9517269D0 (en) * 1995-08-23 1995-10-25 Cortecs Ltd Vaccines
US5993852A (en) * 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
CA2310457A1 (en) 1997-11-21 1999-06-03 Laura Anne Oakes Product applicator
GB2369094A (en) 2000-11-17 2002-05-22 Procter & Gamble Packaging assembly for sheets of water-soluble sachets
WO2002060416A1 (en) * 2001-02-01 2002-08-08 Gendel Limited Polypeptide delivery system and method for their preparation
US20060083702A1 (en) * 2004-04-02 2006-04-20 Thomas Fondin Hair fiber treating method
WO2006068306A2 (en) 2004-12-22 2006-06-29 Fujifilm Corporation COMPOSITION FOR STERILIZATION COMPRISING ω-ALKOXYPEROXYCARBOXYLIC ACID
CA2690973A1 (en) * 2006-06-23 2007-12-27 Paul M. Simon Targeted immune conjugates
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
EP2318832B1 (en) 2008-07-15 2013-10-09 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
GB0901207D0 (en) 2009-01-26 2009-03-11 Innospec Ltd Chelating agents and methods relating thereto
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
WO2011138032A2 (en) 2010-05-05 2011-11-10 Artemev, Timur Universal influenza vaccines and methods for their generation
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
WO2012059112A1 (en) * 2010-11-01 2012-05-10 Mahmoud Abdel Wahed Rafea Development of medical products based on a new discovered function of red blood cells
EP2714017B1 (en) * 2011-06-02 2018-08-01 The Regents of The University of California Membrane encapsulated nanoparticles and method of use
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
AU2012326203B2 (en) 2011-10-17 2017-11-30 Massachusetts Institute Of Technology Intracellular delivery
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
ES2689878T3 (es) 2013-02-21 2018-11-16 Boehringer Ingelheim Vetmedica Gmbh Proteínas H5 del virus de la gripe H5N1 para su uso como un medicamento
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
WO2015023982A1 (en) 2013-08-16 2015-02-19 Massachusetts Institute Of Technology Selective delivery of material to cells
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
JP2017507118A (ja) 2014-01-16 2017-03-16 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ がんの処置および検出のための組成物および方法
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI687428B (zh) 2014-03-27 2020-03-11 中央研究院 反應性標記化合物及其用途
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR102512592B1 (ko) 2014-05-27 2023-03-21 아카데미아 시니카 항-ｈｅｒ2 글리코항체 및 이의 용도
EP3149045B1 (en) 2014-05-27 2023-01-18 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
KR102494193B1 (ko) 2014-05-28 2023-01-31 아카데미아 시니카 항-ｔｎｆ-알파 글리코항체 및 이의 용도
KR102422375B1 (ko) 2014-09-08 2022-07-18 아카데미아 시니카 당지질을 사용한 인간 iNKT 세포 활성화
RU2739794C2 (ru) 2014-10-31 2020-12-28 Массачусетс Инститьют Оф Текнолоджи Доставка биомолекул в клетки иммунной системы
CN107002089B (zh) 2014-11-14 2021-09-07 麻省理工学院 化合物和组合物向细胞中的破坏和场实现的递送
CA2971626A1 (en) 2015-01-12 2016-07-21 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
EP3248005B1 (en) 2015-01-24 2020-12-09 Academia Sinica Novel glycan conjugates and methods of use thereof
CA2988996A1 (en) 2015-07-09 2017-01-12 Massachusetts Institute Of Technology Delivery of materials to anucleate cells
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
JP2019515876A (ja) 2016-03-08 2019-06-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｎ−グリカンおよびそのアレイのモジュール合成のための方法
CN109963868B (zh) 2016-08-22 2023-11-14 醣基生医股份有限公司 抗体、结合片段及使用方法
GB2625450A (en) 2022-12-16 2024-06-19 Innospec Performance Chemicals Italia Srl Compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136167A (en) * 1975-06-12 1979-01-23 Internationale Octrooi Maatschappij "Octropa" B.V. Process for reducing the incidence of neonatal diarrhoea in pigs
DE2551208C3 (de) * 1975-11-14 1981-05-27 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung einer stabilen Erythrozyten-Präparation
FR2355507A1 (fr) * 1976-06-25 1978-01-20 Inst Nat Sante Rech Med Vaccin antiparasitaire par voie orale, son procede de preparation et sa methode d'application chez les mammiferes
SU649435A1 (ru) * 1977-06-24 1979-02-28 Уфимский Научно-Исследовательский Институт Вакции И Сывороток Им. И.И.Мечникова Способ приготовлени эритроцитов
US4403037A (en) * 1980-10-10 1983-09-06 American Hoechst Corporation Erythrocyte preparations and use thereof in hemagglutination tests
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4904468A (en) * 1987-06-08 1990-02-27 Norden Laboratories, Inc. Canine coronavirus vaccine

Also Published As

Publication number Publication date
DE69128782T2 (de) 1998-09-10
HK1004060A1 (en) 1998-11-13
EP0528859B1 (en) 1998-01-21
AU7753191A (en) 1991-11-11
DE69128782D1 (de) 1998-02-26
EP0528859A1 (en) 1993-03-03
EP0528859A4 (en) 1993-08-04
GR3026569T3 (en) 1998-07-31
JPH05506233A (ja) 1993-09-16
BR9106374A (pt) 1993-03-30
SG46225A1 (en) 1998-02-20
KR100186783B1 (ko) 1999-05-01
DK0528859T3 (da) 1998-09-14
ATE162402T1 (de) 1998-02-15
WO1991016073A1 (en) 1991-10-31
US5643577A (en) 1997-07-01
CA2080477A1 (en) 1991-10-25
AU646257B2 (en) 1994-02-17

Similar Documents

Publication Publication Date Title
ES2113882T3 (es) Vacuna oral que comprende un antigeno asociado superficialmente con eritrocitos.
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
FI970799A (fi) Mutanttientoroksiini, joka on tehokas ei-toksinen oraalinen adjuvantti
CO5210894A1 (es) Composiciones adyudantes que comprenden una sal de aluminio y un inmunoestimulante
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
DE69425427D1 (de) Ein pharmazeutisches präparat zur topischen verabreichung von antigenen und/oder vakzinen an die schleimhäute von säugern
ES2098029T3 (es) Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.
DE69943170D1 (de) Immunologische Zusammensetzung und Impfstoffe, die einen auf N-Formyl-Methionyl Peptide bestehenden Adjuvans enthalten
ES2075440T3 (es) Vacuna contra la hepatitis b.
NO940661L (no) Peptider for indusering av cytotoksisk T-lymfocytreaksjoner mot hepatit B virus
HUP9901958A2 (hu) Sertés reproduktív és respirációs szindróma vakcina
AU6383296A (en) Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection
NO913131L (no) Immunogene konjugater av ikke-toksisk oligosakkarid fra bordetella pertussis lipoolysakkarid.
EP0090660A3 (en) Neisseria gonorrhoeae vaccine
Fries et al. Vaccinial infection in children with atopic dermatitis
ATE18007T1 (de) Hepatitisimpfstoff.
DK1416958T4 (da) Vaccinesammensætning, som indeholder mindst to valenser, én med adjuvans og én uden adjuvans
AR012896A1 (es) Polipeptido flge de helicobacter pylori, composicion de vacuna, uso de dicho polipeptido para la fabricacion de composiciones, metodo de diagnostico invitro, y kit de diagnostico para la deteccion de la infeccion por helicobacter pylori
Lionarons et al. Five cases of reactive arthritis after an outbreak of Shigella flexneri infection in the Netherlands.
Schwab et al. Reactions of monkeys to experimental respiratory infections. II. Response to streptococcus hemolyticus group c
FR2724845B1 (fr) Compositions de muramyl peptides capables d'inhiber jusqu'a 100% la replication d'un virus de l'immuno-deficience acquise, tel que le vih
AR011592A1 (es) Metodo de creacion, o mantenimiento o para inducir una inmuno respuesta protectora o adaptativa a un virus hiv en un huesped
WO2000012129A3 (en) Salmonella typhi vaccine compositions
Tyroler El Salvador: Death Squads Suspected In Recent Killings
NO905619D0 (no) Identifikasjon av human-t-lymfocyt-epitoper i patogener for vaksine-utvikling.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 528859

Country of ref document: ES